Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York

Charles J. Neighbors 1*, Sugy Choi 1,2, Shannon Healy 1, Rajeev Yerneni 1, Tong Sun 3 and Liudmila Shapoval 1

Abstract

Background: Medication for addiction treatment (MAT) has received much attention in recent years for treating individuals with opioid use disorders (OUD). However, these medications have been significantly underused among particular subgroups. In this paper, we describe the age distribution of treatment episodes for substance use disorder among Medicaid beneficiaries in New York and corresponding MAT use.

Methods: Using New York Medicaid claims, we identified individuals with OUD that received treatment for substance use disorder in 2015. The type of substance use treatment is the primary outcome measure, which includes methadone, buprenorphine, naltrexone or other non-medication treatment.

Results: A total of 88,637 individuals were diagnosed with OUD and received treatment for substance use disorder and 56,926 individuals received some type of MAT in 2015, with 40.2% receiving methadone, 21.9% receiving buprenorphine and 2.2% receiving naltrexone while 21.9% received non-medication based treatment. Young adults (ages 18–29) were a large proportion (25%) of individuals in treatment for OUD yet were the least likely to receive MAT. Relative to young adults, 30–39 year olds (adjusted odds ratio [AOR] = 1.62, 95% CI = 1.56–1.68), 40–49 year olds (AOR = 1.90, 95% CI = 1.82–1.99), 50–59 year olds (AOR = 2.65, 95% CI = 2.52–2.78), and 60–64 year olds (AOR = 5.03, 95% CI = 4.62–5.48) were more likely to receive MAT.

Conclusions: These preliminary findings highlight high numbers of young adults in treatment for OUD and low rates of MAT, which is not consistent with treatment guidelines. Significant differences exist in the type of medication prescribed across age. More attention is needed to address the treatment needs among individuals of different age, notably young adults.

Keywords: Opioid use disorder, Medication for addiction treatment, Medication-assisted treatment, MAT, Medicaid, Substance use disorder

Background

Individuals with opioid use disorder (OUD) have high mortality, morbidity, and low remission rates [1, 2]. Medication for addiction treatment (MAT) is effective for treating OUD and multiple guidelines recommend the use of MAT—methadone, buprenorphine, naltrexone—for the treatment [3–6]. Research on MAT utilization has received much attention in recent years, but despite the robust scientific evidence and commensurate clinical guidelines recommending their use, these medications are significantly underused [7].

The opioid epidemic disproportionately affected Medicaid beneficiaries [8–10]. For instance, Medicaid beneficiaries ages 18 to 64 have a higher rate of OUD compared to privately insured individuals, comprising about 12% of all adults in this age group in 2015 [8]. Medicaid beneficiaries are more likely to experience negative health outcomes, such as overdose than those with other sources of insurance [11, 12]. Medicaid beneficiaries, especially youth, had higher rates of substance use disorders compared to privately-insured youth. Medicaid beneficiaries with an OUD have higher substance
use disorder treatment rates than privately insured adults with the same condition [8].

Medicaid-covered medication treatment of OUD has increased dramatically between 2011 and 2016, from $394.2 million to $929.9 million [9]. Yet, research on MAT patterns of Medicaid beneficiaries who utilized some type of substance use disorder (SUD) treatment is limited. Existing studies of publicly funded treatment indicate low rates of MAT and even lower rates among youth [13, 14]. Since 2001, New York State has offered Medicaid coverage to low-income uninsured single adults, providing some experience that can inform other states that extend Medicaid coverage to non-elderly, childless adults [15]. The New York Medicaid program is one of the largest in the U.S. in terms of cost and total people covered and has been a large funder of SUD treatment services provided in the state [16, 17].

Overall, age is an important factor to consider when examining patterns of behavioral health and health services utilization. Although age is an important characteristic that is associated with access to substance use treatment, often, studies do not directly compare the young adults (ages 18–29) to those of other age groups. Despite the fact that young adults are undergoing a unique developmental period, there is limited understanding of the rates of evidence-based practice, OUD treatment, among young adults [18]. Since young adulthood is characterized by unique neurodevelopment and psychosocial adjustment, engaging young adults in treatment may require a different strategy than with older adults [18]. Existing studies in New York have focused on older beneficiaries [19] and young adults are an understudied population. [20, 21] Access to substance use disorder treatment services have been challenging, especially for young adults who prefer buprenorphine and naltrexone compared to methadone [22, 23], as limited access to buprenorphine providers have been an ongoing problem [24]. Age effects of the current epidemic have been understudied, especially research on MAT [25]. In this paper, we examine the use of the different types of SUD treatment (methadone, buprenorphine, naltrexone, other non-medication treatment) by age groups among patients who have at least one OUD diagnosis and at least one treatment episode for SUD in the New York State Medicaid population. We hypothesized that young New York Medicaid beneficiaries aged 18 to 29 in our sample will be less likely to engage in MAT compared to older Medicaid beneficiaries.

Methods
Our analysis is based on New York Medicaid data for the calendar year 2015 for beneficiaries aged 18 to 64. International classification of disease diagnoses codes (ICD-10) was used to identify patients with at least one OUD diagnosis and procedure codes from Current Procedural Terminology or International Classification of Disease systems, prescription national drug codes, or from New York Medicaid specific reimbursement codes indicating SUD treatment were used to identify patients who received at least one treatment for SUD in 2015. Patients with health insurance coverage through both Medicaid and Medicare were excluded because we were unable to access the entirety of their healthcare claims data.

The primary outcome of interest was the type of SUD treatment utilization that patients received in 2015. Patients were classified as having received methadone, buprenorphine or naltrexone treatment if they were identified with at least one methadone maintenance therapy visit, or if they filled at least one buprenorphine or naltrexone-based prescription. Among those who did not receive MAT, we defined SUD treatment based on billing procedure codes from Current Procedural Terminology or ICD-10, or from New York Medicaid specific reimbursement codes indicating SUD treatment. Treatment included inpatient, outpatient, or psychotherapy care with a SUD diagnosis yet, it excluded detoxification services if not followed by specific treatment for substance use disorder. We created four mutually exclusive groups: methadone, buprenorphine, naltrexone and other treatment. For those patients who used multiple medications, we assigned them to the category of their most frequently used medication.

The following six sociodemographic variables, including age group (18–29, 30–39, 40–49, 50–59, 60–64 years), place of residence (New York City (NYC), outside NYC), race and ethnicity (non-Hispanic white, black, Latinx, other, unknown), sex (female, male), and Medicaid eligibility months were considered in the analysis.

Treatment utilization was graphically displayed by age group to help highlight age patterns in the data. The x-axis represents age groups and the y-axis indicates the percentage of patients or number of patients who utilized methadone, buprenorphine, naltrexone, or other SUD treatment without medication treatment. Descriptive statistics were performed by age group. We conducted two sample z-test and t-test to compare the outcome measures and covariates across each age group. We estimated multivariable logistic regression models to identify age group differences in OUD MAT utilization after adjusting for individual covariates. All statistical analyses were conducted using SAS 9.4 and STATA M.P.13.

Results
In total, 88,637 individuals aged 18–64 received at least one treatment for SUD among 111,033 individuals who had at least one OUD diagnosis in 2015. Figure 1 shows that young adults (ages 18–29) highlight a large proportion of beneficiaries who have received treatment for OUD (25% of all individuals in treatment for OUD), yet only 49.2% were receiving MAT compared to 62.4% of
30 to 39 year olds who received MAT. Overall, 64.2% of all individuals in treatment for OUD received some type of MAT in 2015, with 40.2% receiving methadone, 21.9% receiving buprenorphine and 2.2% receiving naltrexone while 35.8% received non-medication based treatments. Of those receiving non-medication based treatment, the majority of patients (81.5%) received outpatient behavioral care services, while 5.1% only had inpatient care, and 13.4% received a combination of inpatient and outpatient services during the year.

Demographic characteristics varied by age for this sample (Table 1). Young adults (18–29 years old) are less racially diverse than older age groups, with nearly 73.3% identifying as non-Hispanic white, compared to 64.6% of 30–39 year olds, 35% of 40–49 year olds, 20.9% of 50–59 year olds, and 20.2% of 60–64 year olds. Young adults had greater proportions of females (39.9%) compared to only 38.8, 32.4, 32.3, and 31.9% of 30–39, 40–49, 50–59, and 60–64 year olds, respectively. Additionally, 79.8% of young adults reside outside of New York City compared to 69.5% of 30–39 year olds, 40.7% of 40–49 year olds, 25% of 50–59 year olds, and only 20.3% of 60–64 year olds. The mean length of Medicaid eligibility months was 10.6 months for young adults compared to 10.9 months for 30–39 year olds, 11.1 months for 40–49 year olds, 11.4 months for 50–59 year olds, and 11.5 months for 60–64 year olds, respectively.

The percentages of patients who received MAT were significantly larger in older patients compared with young adults. Older age groups had a higher prevalence of MAT than younger groups with 84.4% of those aged 60–64 receiving some type of medication for addiction treatment compared to 74.9% of those aged 50–59, 68.4% of those aged 40–49, 62.4% of those aged 30–39 and 49.2% of young adults aged 18–29. In adjusted comparisons (Table 2), older patients, 30–39 year olds (AOR = 1.62, 95% CI = 1.56–1.68), 40–49 year olds (AOR = 1.90, 95% CI = 1.82–1.99), 50–59 year olds (AOR = 2.65, 95% CI = 2.52–2.78), and 60–64 year olds (AOR = 5.03, 95% CI = 4.62–5.48) were more likely to receive medication treatment for OUD compared to young adults. Latinx (AOR = 1.08, 95% CI = 1.03–1.14) and beneficiaries living in NYC (AOR = 2.29, 95% CI = 2.21–2.38) were more likely to receive MAT compared to Non-Hispanic whites and beneficiaries living outside NYC, respectively. Non-Hispanic blacks (AOR = 0.36, 95% CI = 0.34–0.38) and females (AOR = 0.73, 95% CI = 0.71–0.75) were less likely to receive MAT compared to Non-Hispanic whites and females.

**Discussion**

This study examines MAT utilization by age groups among Medicaid beneficiaries identified with OUD who received at least some type of SUD treatment in 2015. Our results demonstrate that young adults are a large proportion of Medicaid beneficiaries in treatment for OUD yet are less likely to receive MAT. Notably, we found the use of MAT among the Medicaid beneficiaries with OUD is higher compared to what has been previously reported by the National Surveys on Drug Use and Health [26]. This alludes that Medicaid coverage may facilitate access to SUD treatment yet highlights the need for extra attention to young adults.

Only half of young adults received MAT for OUD, and the older patients were more likely to receive MAT. A recent study of commercial claims data from 2001 to 2014 found that only 25% of youth (adolescents and young adults, ages 13–25) with OUD received any form of medications for OUD [27]. The low rates of MAT among young adults who received treatment for SUD is concerning as previous studies have shown the efficacy of MAT and less likelihood of relapse among young adults [14, 27]. The low proportion of individuals receiving MAT is not concordant with standard treatment guidelines [3, 6]. The findings highlight a need to understand why MAT is less likely to be used as a treatment...
for OUD among young adults compared to other age groups and address this gap in care practices. Medication utilization differed across the age groups, with relatively high use of buprenorphine among young adults and relatively high use of methadone among older patients. This may be due to the differences in patient or provider attitudes toward MAT where young adults favoring buprenorphine compared to methadone. The higher rates of methadone use among older adults have been previously reported and may reflect older individuals entering treatment before buprenorphine became available or who having greater clinical case complexity for which methadone programs are better suited. Previous studies document the importance of community attitudes about the appropriateness of medications for youth, many patients and treatment providers have been reluctant to use medications in early episodes of care for OUD.

Further research is needed on the types and quality of treatment available to youth and young adults with OUD. Brain development extends into the mid 20's, which means that youth are passing through a heightened period of vulnerability from exposure to substances. Not only is this period a time of increased risk of developing substance use dependence but also a time when prolonged exposure to substances can have lasting effects on brain development. This developmental transition presents a dilemma when there are also concerns that the MAT can also create lasting changes in the brain. Because of these concerns and because of community attitudes about the appropriateness of medications for youth, many

Table 1 Demographics characteristics and Medication-assisted treatment (MAT) use by age groups

| Age          | 18–29 n = 22,270 | 30–39 n = 24,314 | 40–49 n = 17,819 | 50–59 n = 19,184 | 60–64 n = 9,050 | Total n = 88,637 |
|--------------|-----------------|-----------------|-----------------|-----------------|----------------|-----------------|
| Race n (%)   |                 |                 |                 |                 |                |                 |
| Non-Hispanic White | 16,327 (73.3) | 15,697*** (64.6) | 6237*** (35.0) | 4001*** (20.9) | 1019*** (20.2) | 43,281 (48.8) |
| Non-Hispanic Black | 1577 (7.1) | 1951*** (8.02) | 3074*** (17.3) | 5475*** (28.5) | 1696*** (33.6) | 13,773 (15.5) |
| Latinx | 1688 (7.6) | 3792*** (15.6) | 5830*** (32.7) | 6926*** (36.1) | 1674*** (33.2) | 19,910 (22.5) |
| Other | 1282 (5.8) | 1894*** (7.8) | 2107*** (11.8) | 2366*** (12.3) | 586*** (11.6) | 8235 (9.3) |
| Unknown | 1396 (6.3) | 980*** (4.0) | 571*** (3.2) | 416*** (2.2) | 75*** (1.5) | 3438 (3.9) |
| Gender n (%) |                 |                 |                 |                 |                |                 |
| Female | 8874 (39.9) | 9429* (38.8) | 5766*** (32.4) | 6199*** (32.3) | 1611*** (31.9) | 31,879 (36.0) |
| Male | 13,396 (60.2) | 14,885** (61.2) | 12,053*** (67.6) | 12,985*** (67.7) | 3439*** (68.1) | 56,758 (64.0) |
| Location n (%) |                 |                 |                 |                 |                |                 |
| New York City (NYC) | 4502 (20.2) | 7428*** (30.6) | 10,562*** (59.3) | 14,385*** (35.0) | 4023*** (80.0) | 40,900 (46.1) |
| Outside NYC | 17,768 (79.8) | 16,886*** (69.5) | 7257*** (40.7) | 4799*** (25.0) | 1027*** (20.3) | 47,737 (53.9) |
| Mean Medicaid eligibility months, (standard deviation) | 10.6 (2.5) | 10.0*** (2.3) | 11.1*** (2.1) | 11.4*** (1.8) | 11.5*** (1.6) | 11.0 (2.2) |
| Treatment Utilization n (%) |                 |                 |                 |                 |                |                 |
| Medication-Assisted Treatment (MAT) | 10,948 (49.2) | 15,172*** (62.4) | 12,181*** (68.4) | 14,363*** (74.9) | 4262*** (84.4) | 56,926 (64.2) |
| Methadone | 3950 (17.7) | 7209*** (25.7) | 8554*** (48.0) | 12,034*** (62.7) | 3868*** (76.6) | 35,615 (40.2) |
| Naltrexone | 656 (3.0) | 584*** (2.4) | 374*** (2.1) | 278*** (1.5) | 37*** (0.7) | 1929 (2.2) |
| Buprenorphine | 6342 (28.5) | 7379*** (30.4) | 3253*** (18.3) | 205*** (10.7) | 357*** (7.1) | 19,382 (21.9) |
| Non-Medication Treatment | 11,322 (50.8) | 9142*** (37.6) | 5638*** (31.6) | 4821*** (25.1) | 788*** (15.6) | 31,711 (35.8) |

*p-value calculated from two sample z-test and t-test to compare patients in each age group with 18–29 year olds. *p < 0.05, **p < 0.01, ***p < 0.001
patients and treatment providers have been reluctant to use medications in early episodes of care for OUD [29, 31, 32]. Often when MAT is incorporated into care, treatment professionals and patients/family members will use medications for a brief transition period with the expectation that the youth quickly move into medication-free psychosocial treatment to maintain recovery. However, two studies have found that rapid tapering of youth off medications leads to a heightened risk of relapse [37, 38]. More research is needed to investigate the appropriate lengths of MAT among young adults. Generally, a briefer MAT treatment duration is associated with poor outcomes [39–42]. Yet, when medications are incorporated into treatment, younger individuals are less compliant and more likely to quit treatment than older individuals [43, 44]. All of this raises critical questions about the risk/benefits of longer-term treatment with medications for youth. Both treatment providers and patients/family members need more evidence about the relative effectiveness of MAT for OUD for treatment planning during initial phases of care [18, 33].

This study has several limitations. This is a cross-sectional analysis of data without individual clinical factors, such as the severity of OUD, so findings indicate associations rather than cause and effect relationships. Our sample has been restricted to those who have OUD diagnosis, but not all individuals who receive treatment for OUD have a formal OUD diagnosis [45]. The data only captures treatment services that have been billed through Medicaid in New York. While New York has a large, diverse population and treatment system for substance use disorders funded through its Medicaid program, the findings may not mirror patterns of care in other regions. Finally, our use of Medicaid data to document MAT utilization for substance use disorders does not cover potential treatment events that were not reimbursed by Medicaid. However, the individuals in this study are identified with OUD to Medicaid, which covers the large proportion of individuals with SUD in the United States and is an important component of healthcare reform [46].

**Conclusions**

We found large numbers of young adults seeking treatment for OUD, low use of MAT, and differences in medication use by age. Future research is needed to identify how to increase the uptake of MAT while attending to specific needs across different age groups. Especially, more research is needed for engaging young adults who have disproportionately low rates of using MAT after engaging in SUD treatment. Public health officials and treatment providers should consider age group effects in designing individually tailored interventions for patients for engagement with medications in the course of their OUD treatment.

**Abbreviations**

ICD-10: International classification of disease diagnoses codes; MAT: Medication for addiction treatment; NYC: New York City; OUD: Opioid use disorder; SUD: Substance use disorder

**Table 2** Multivariable regression analyses of the relationship between age group and receipt of MAT

| Age group | Crude Odds Ratio | 95% Confidence Interval | Adjusted Odds Ratio | 95% Confidence Interval |
|-----------|-----------------|-------------------------|---------------------|-------------------------|
| 18–29     | Reference       | Reference               |                     |                         |
| 30–39     | 1.72***         | 1.65–1.78               | 1.62***             | 1.56–1.68               |
| 40–49     | 2.23***         | 2.14–2.33               | 1.90***             | 1.82–1.99               |
| 50–59     | 3.08***         | 2.95–3.21               | 2.65***             | 2.52–2.78               |
| 60–64     | 5.59***         | 5.16–6.06               | 5.03***             | 4.62–5.48               |
| Race n    |                 |                         |                     |                         |
| Non-Hispanic White | Reference | Reference               |                     |                         |
| Non-Hispanic Black | 0.82***         | 0.79–0.85               | 0.36***             | 0.34–0.38               |
| Latinx    | 2.39***         | 2.30–2.49               | 1.08***             | 1.03–1.14               |
| Other     | 1.40***         | 1.33–1.48               | 0.67***             | 0.63–0.71               |
| Unknown   | 0.63***         | 0.59–0.68               | 0.52***             | 0.48–0.56               |
| Gender    |                 |                         |                     |                         |
| Female    | Reference       | Reference               |                     |                         |
| Male      | 0.83***         | 0.81–0.86               | 0.73***             | 0.71–0.75               |
| Location  |                 |                         |                     |                         |
| Outside NYC | Reference     | Reference               |                     |                         |
| NYC       | 2.48***         | 2.41–2.55               | 2.29***             | 2.21–2.38               |

*p < 0.05, **p < 0.01, ***p < 0.001
Acknowledgements

None.

Authors’ contributions

CN, RY, SC and SH conceptualized study. SC and SH prepared the first draft of the analysis. SC, SH and TS conducted the statistical analysis. All authors contributed to the main contents and provided critical comments on the final draft. All authors approved the final manuscript.

Funding

This work was supported by the National Institutes of Health [grant numbers R33DA035615, R01DA038193, 1T32DA041898]. The funding agencies had no role in study design, in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Availability of data and materials

The data are provided by the New York Department of Health, who have strong safeguards and access restrictions to protect individual privacy. The New York Department of Health did not participate in preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the New York Department of Health.

Ethics approval and consent to participate

This research was approved by Center on Addiction institutional review board, protocol #213.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Center on Addiction, New York, NY, USA. 2Boston University School of Public Health, Boston, MA, USA. 3New York State Office of Alcoholism and Substance Abuse Services (OASAS), Albany, NY, USA.

Received: 15 February 2019 Accepted: 30 May 2019

Published online: 25 June 2019

References

1. Hser YI, et al. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76–89.
2. Soknack P. The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol. 2018;58:143–59.
3. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–67.
4. Committee On Substance, U.S.E. and Prevention, Medication-Assisted Treatment of Adolescents With Opioid Use Disorders. Pediatrics. 2016. 138(3).
5. Pietras S, Azur M, Brown J. Review of medication assisted treatment guidelines and measures for opioid and alcohol use. Washington, DC: Assistant Secretary for Planning and Evaluation; 2015.
6. Committee On Substance Use And Prevention, Medication-Assisted Treatment of Adolescents With Opioid Use Disorders. Pediatrics. 2016. 138(3).
7. Volkow ND. Medications for opioid use disorder: bridging the gap in care. Lancet. 2017.
8. Report to Congress on Medicaid and CHIP June 2017, 2017. MACPAC.
9. Clemans-Cope, L, M, Epstein, and G. Kenney. Rapid growth in Medicaid spending on medications to treat opioid use disorder and overdose. 2017. Urban Institute Health Policy Center.
10. Huhn AS. Serious about the opioid epidemic? Expand Medicaid. Med Care. 2018;56(5):455.
11. Sharp MJ, et al. Poisoning deaths involving opioid analgesics - New york state, 2003-2012. MMWR Morb Mortal Wky Rep. 2015;64(4):377–80.
12. Zhou C, Florence CS, Dowell D. Payments for opioids shifted substantially to public and private insurers while consumer spending declined, 1999-2012. Health Aff (Millwood). 2016;35(5):824–31.
13. Feder KA, Krawczyk N, Saloner B. Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. J Adolesc Health. 2017;60(6):747–50.
14. Hadland SE, et al. Receipt of timely addiction treatment and Association of Early Medication Treatment with Retention in care among youths with opioid use disorder. JAMA Pediatr. 2018.
15. Sommers BD, Baicker K, Epstein AM. Mortality and access to care among adults after state Medicaid expansions. N Engl J Med. 2012.
16. Health, N.Y.S.D.o., A Plan to Transform the Empire State's Medicaid Program, Multi-Year Action Plan. 2011: Albany, NY.
17. Fund, Mi.A.u.h., Providing care to Medicaid beneficiaries with behavioral health conditions: challenges for New York. 2011: New York, NY.
18. Chang DC, et al. Medication-assisted treatment for youth with opioid use disorder: current dilemmas and remaining questions. Am J Drug Alcohol Abuse. 2017:1–4.
19. Han B, et al. Demographic trends of adults in new York City opioid treatment programs—an aging population. Subst Use Misuse. 2015;50(1):1660–7.
20. Davis JP, Smith DC, Briley DA. Substance use prevention and treatment outcomes for emerging adults in non-college settings: a meta-analysis. Psychol Addict Behav. 2017;31(3):242–54.
21. Smith, D.C., Emerging adults and substance use disorder treatment: developmental considerations and innovative approaches. 2018, New York, NY: Oxford University Press. xi, 277 pages.
22. Fishman MJ, et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105(9):1660–76.
23. Borodovsky JT, et al. Buprenorphine treatment for adolescents and young adults with opioid use disorders: a narrative review. J Addict Med. 2018;12(3):170–83.
24. Hansen HB, et al. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in new York City. J Behav Health Serv Res. 2013;40(3):367–77.
25. Huang X, Keyes KM, Li G. Increasing prescription opioid and heroin overdose mortality in the United States, 1999-2014: an age-period-cohort analysis. Am J Public Health. 2017;61–6.
26. Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–27.
27. Hadland SE, et al. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017;171(8):747–55.
28. Hansen H, et al. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in new York City. Drug Alcohol Depend. 2016;164:14–21.
29. Moore SK, Guarino H, Marsh LA. “this is not who I want to be”: experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment. Subst Use Misuse. 2014;49(3):303–14.
30. Cotton BP, et al. Characteristics of Medicaid recipients in methadone maintenance treatment: a comparison across the lifespan. J Subst Abus Treat. 2018;92:40–5.
31. Fiellin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA. 2008;300(17):1057–9.
32. Guarino HM, et al. Methadone maintenance treatment for youth: experiences of clients, staff, and parents. Subst Use Misuse. 2009;44(14):1979–89.
33. Minozzi S, et al. Maintenance treatments for opiate -dependent adolescents. Cochrane Database Syst Rev. 2014;6:CD007210.
34. Pecoraro A, et al. Pharmacologically assisted treatment of opioid-dependent youth. Paediatr Drugs. 2013;15(6):449–58.
35. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160(6):1041–52.
36. Office of Surgeon General. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington (DC): US Department of Health and Human Services; 2016.
37. Marsch LA, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111(8):1401–52.
38. Woody GE, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth a randomized trail. JAMA. 2008;300(17):2003–10.
39. Mattick RP, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
40. Weiss RD, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–46.

41. Gruber VA, et al. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008;94(1–3):199–206.

42. Sees KL, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–10.

43. Schuman-Olivier Z, et al. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abus Treat. 2014;47(3):202–12.

44. Matson SC, et al. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. J Addict Med. 2014;8(3):176–82.

45. Daubresse M, et al. Non-buprenorphine opioid utilization among patients using buprenorphine. Addiction. 2017;112(6):1045–53.

46. Padwa H, et al. Organizing publicly funded substance use disorder treatment in the United States: moving toward a service system approach. J Subst Abus Treat. 2016;699–18.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.